Cassidy Erin L, Lauderdale Sean, Sheikh Javaid I
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, USA.
J Geriatr Psychiatry Neurol. 2005 Jun;18(2):83-8. doi: 10.1177/0891988705276060.
The frequent comorbidity of anxiety and depression, particularly among elderly, is widely recognized by clinicians, but the debate continues as to whether the combined diagnostic designation is merited. This article reviews the debate over the mixed diagnosis, discusses treatment implications, and reviews a small treatment study undertaken with elderly patients. Ten community-dwelling, older adults diagnosed with generalized anxiety disorder and subsyndromal depression (n = 6) or generalized anxiety disorder and major depressive disorder (n = 4) were started on a 12-week, open-label trial of nefazodone. Clinicians' ratings on the Clinical Global Impression of Change and patients' self-ratings of symptoms on the Beck Depression Inventory and the Beck Anxiety Inventory identified statistically significant gains in patients' overall pre/post functioning. Nefazodone was efficacious in symptom alleviation in patients with comorbid anxiety and depression. Further double-blind, randomized investigations with newer antidepressant medications are required to extend these preliminary findings with nefazodone.
焦虑症和抑郁症常合并出现,在老年人中尤为常见,这一点已得到临床医生的广泛认可,但对于联合诊断名称是否合理仍存在争议。本文回顾了关于混合诊断的争论,讨论了治疗意义,并回顾了一项针对老年患者的小型治疗研究。10名居住在社区的老年人被诊断为广泛性焦虑症合并亚综合征性抑郁症(n = 6)或广泛性焦虑症合并重度抑郁症(n = 4),他们开始了为期12周的奈法唑酮开放标签试验。临床医生对临床总体印象变化的评分以及患者在贝克抑郁量表和贝克焦虑量表上对症状的自我评分显示,患者在治疗前后的整体功能有统计学上的显著改善。奈法唑酮对合并焦虑症和抑郁症的患者在症状缓解方面有效。需要进一步使用更新的抗抑郁药物进行双盲、随机研究,以扩展这些关于奈法唑酮的初步研究结果。